FDA Panel Says Amgen Lung Cancer Drug Data Cannot Be Relied on

Advisers to the US Food and Drug Administration on Thursday found that data from a late-stage trial of Amgen's Lumakras could not be relied on.

Related Keywords

Los Angeles ,Pratik Jain ,Bhanvi Satija ,Deena Beasley ,Harpreet Singh ,Amgen Lumakras ,Reuters ,Drug Administration On ,Amgen ,Drug Administration ,Bill Berkrot ,Non Small Cell Lung Cancer ,Nsclc ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Lung ,Skras ,K Ras ,V Ki Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog ,Gtpase Kras ,